Amwell Q3 2026 Earnings Call - AMERICAN WELL CORP

Financial Performance:

• Q3 2026 total revenue was $49 million, down 12.9% YoY but $1 million above the high end of guidance; subscription revenue declined 22.5% YoY (reflecting prior churn), while AmWell Medical Group (AMG) revenue rose 11.7% YoY.
• AMG visit revenue reached $23.7 million with 301,000 paid visits; revenue per visit increased 11% YoY to ~$79, driven by favorable pricing and a mix shift toward higher-value virtual primary care (up 41% YoY).
• Gross margin improved to 53% (up 57 bps YoY) due to cost containment and higher clinical program revenue.
• Adjusted EBITDA loss narrowed to $3.6 million (a $9.1 million YoY improvement), while operating loss decreased 60% YoY to $11.7 million.
• Operating expenses fell 36% YoY to $37.6 million (76.8% of revenue); balance sheet remains strong with $181 million in cash/investments and zero debt.

Guidance and Future Outlook:

• Q4 2026 revenue guidance raised to $48–$50 million (previously lower); adjusted EBITDA guidance set to break-even or positive $1 million.
• Full-year 2026 revenue guidance raised to $204–$206 million (prior: $195–$205 million); full-year adjusted EBITDA loss narrowed to $6.9–$7.9 million (prior: $12–$16 million loss).
• Management targets positive cash flow from operations and positive adjusted EBITDA in Q4 2026, with 9 consecutive quarters of meeting commitments.
• 2027 full-year guidance to be provided on February 16, 2027; current outlook anticipates growth driven by activation and new government contract onboarding.

Business Segments and Product Lines:

• Platform Strategy: Focused on a single unified platform to solve vendor sprawl, replacing fragmented point solutions with one integration, consistent member experience, and outcome-based data.
• AMG (Clinical Services): Virtual primary care growing 41% YoY; behavioral health module (SilverCloud) showing strong outcomes (60–78% improvement in depression cases) with hospital cost reductions of 6%.
• Member Experience: Shipped a simplified 3-screen UX; member ratings at 4.9/5; engagement rates triple when fully activated vs. dormant.
• Government Contracts: Received Letter of Intent (LOI) from Department of Veterans Affairs (serving 9.6M beneficiaries) to deploy platform; DHA (Defense Health Agency) contract transition to a direct, longer-term agreement is in final negotiations.
• New Initiatives: Rapid partner onboarding (weeks vs. months) to allow customers to test programs; expanding US behavioral health offerings to match international success.

Market and Competitive Landscape:

• Health plans and employers face 8–11% cost increases in 2027, shifting purchasing criteria from "access" to "engagement and proven outcomes."
• AI integration is accelerating program creation; 30% of adults use AI for health info monthly, increasing the need for clinician-in-the-loop verification.
• Competitive Differentiation: Amwell positions itself as a trusted platform extending client brands rather than competing with them, offering "outcome-based" contracting vs. traditional SaaS.
• Market Share: Currently serves >90 million covered lives and the entire Military Health System (9.6M beneficiaries); VA expansion offers access to a new significant addressable market.

Risks and Challenges:

• Subscription Churn: Continued decline in subscription revenue due to legacy churn, though management expects this trend to stabilize in Q4 and minimize large swings in 2027.
• Contract Execution: VA LOI is not a binding contract; definitive agreement requires federal procurement negotiation, with implementation expected early next year.
• Revenue Mix Shift: Transition from SaaS to outcome-based pricing may alter revenue recognition timing and volume drivers in the near term.
• Execution Risk: Successful capitalization on VA/DHA opportunities depends on contract finalization and integration speed.

Management Commentary and Tone:

• Tone: Confident, disciplined, and focused; management highlighted "nine quarters in a row" of delivering guidance.
• Strategic Narrative: Emphasized "activation" as the key lever for growth, citing single-digit engagement rates in the industry as a major untapped opportunity.
• Efficiency: Repeated commitment to a lean cost structure and "focus" on the single AmWell platform, expecting to grow revenue without significant headcount increases.

Analyst Questions and Answers:

• VA/DHA Timeline: Management confirmed detailed negotiations for VA are underway with optimism for a contract soon; DHA conversion to a direct contract is near completion.
• Growth Drivers: Analysts noted potential mid-teens growth for 2027; management agreed on pipeline strength but cautioned that contract start dates may push revenue impact into late 2027/early 2028.
• Engagement Metrics: Confirmed that 3x engagement increase drives value; management views clinical revenue (AMG + partners) as the primary growth engine, potentially overshadowing SaaS revenue long-term.
• Churn Stabilization: Confirmed that major plan-related churn is likely behind, with only natural churn remaining in de-emphasized business lines.
• Headcount/efficiency: Clarified that even with new government contracts, the company expects to maintain discipline with no material headcount growth due to AI-driven efficiency.

Other Key Points:

• Recognitions: AmWell named "Technology Innovation Leadership" by Forrester (referred to as Forst & Sullivan in transcript) and to Time Magazine's top health tech companies of 2026.
• SilverCloud: International case study with Discovery Health cited 22,000 activated members and significant mental health cost reductions.
• Data Strategy: Utilization of a common data structure to standardize outcomes reporting and prove ROI to customers.
• Pricing Evolution: Shift anticipated toward outcome-based pricing models that share risk and upside with payers.